For health care consumers, the promise of the modern prescription drug system is straightforward: competition should lower prices, intermediaries should add value, and savings should flow to patients. A recent investigation suggests the reality is something quite different. In practice, the system appears structured to extract value from consumers while obscuring where their money actually goes. The complex PBM shell game often operates to the detriment of consumers and small, independent pharmacies that lack the leverage to compete.

In the article resulting from the investigation, authors detail how major pharmacy benefit managers — including subsidiaries tied to CVS Caremark, UnitedHealth’s Optum Rx, and Cigna’s Express Scripts— have created opaque “PBM GPO” entities that appear designed to retain billions in drug manufacturer rebates while publicly claiming those rebates are fully passed through to health plans. These entities operate out of nominal or vacant offices and rely on contractual complexity and regulatory safe harbors never intended for this use.
Read the investigation here.

The consequences flow downstream. Consumers face higher list prices and premiums, while everyone struggles to understand why promised savings never materialize. Independent pharmacies — already operating on thin margins — are squeezed further, competing against vertically integrated giants that control pricing, reimbursement, and access. Unlike large chain pharmacies affiliated with PBMs, independent operators lack insight into rebate flows and lack bargaining power within a system that appears intentionally difficult to decipher.

What emerges is not merely a transparency problem, but a structural one. The system rewards complexity, consolidation, and opacity, while penalizing smaller participants and the patients they serve. When rebates intended to lower costs are redirected into hidden revenue streams, the market stops functioning as a market at all.

The Hunterbrook investigation highlights a fundamental unfairness baked into the prescription drug supply chain. If meaningful reform is to occur, it will require more than tinkering with prices. It will require confronting the intermediary structures that profit from confusion — and asking whether a system that consistently disadvantages consumers and independent pharmacies is operating as intended, or merely as designed.